加载中
NASDAQHealthcareBiotechnology
最新数据
US$1.4716
+US$0.0016 · +0.11%
Enveric Biosciences, Inc. is a pharmaceutical firm focused on advancing diverse cannabinoid-based medications, primarily for use in cancer care. The company's robust product pipeline includes EV104, developed for treating osteoarthritis, and EVM-101 and EVM-201, which are intended to alleviate cancer-related distress. Furthermore, EVM-301 is under development for a mental health indication, alongside EV102, a cannabinoid cream formulated for topical skin application. Rounding out their portfolio is EV101, a novel combination therapy integrating cannabinoids with chemotherapy. This innovative company is based in Naples, Florida.
常规交易时段
US$1.4716
+US$0.0016 · +0.11%
盘中时间采用ET。市场数据可能有所延迟。
Enveric Biosciences, Inc. is a pharmaceutical firm focused on advancing diverse cannabinoid-based medications, primarily for use in cancer care. The company's robust product pipeline includes EV104, developed for treating osteoarthritis, and EVM-101 and EVM-201, which are intended to alleviate cancer-related distress. Furthermore, EVM-301 is under development for a mental health indication, alongside EV102, a cannabinoid cream formulated for topical skin application. Rounding out their portfolio is EV101, a novel combination therapy integrating cannabinoids with chemotherapy. This innovative company is based in Naples, Florida.
日内区间
当前US$1.4716
52周区间
当前US$1.4716
盘中时间采用ET。市场数据可能有所延迟。
Enveric Biosciences, Inc. is a pharmaceutical firm focused on advancing diverse cannabinoid-based medications, primarily for use in cancer care. The company's robust product pipeline includes EV104, developed for treating osteoarthritis, and EVM-101 and EVM-201, which are intended to alleviate cancer-related distress. Furthermore, EVM-301 is under development for a mental health indication, alongside EV102, a cannabinoid cream formulated for topical skin application. Rounding out their portfolio is EV101, a novel combination therapy integrating cannabinoids with chemotherapy. This innovative company is based in Naples, Florida.
日内区间
当前US$1.4716
52周区间
当前US$1.4716
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 销货成本 | 20.09万 USD | 33.75万 USD | 40.8万 USD | 43.52万 USD | 68.16万 USD |
| 毛利 | −20.09万 USD | −33.75万 USD | −40.8万 USD | −43.52万 USD | −68.16万 USD |
| 研究与开发 | 278.1万 USD | 284.13万 USD | 725.24万 USD | 802.78万 USD | 478.88万 USD |
| 销售、一般及管理费用 | 579.26万 USD | 645.35万 USD | 878.8万 USD | 1149.85万 USD | 2047.41万 USD |
| 营业费用 | 857.36万 USD | 929.48万 USD | 1604.04万 USD | 1952.62万 USD | 2526.29万 USD |
| 利息收入 | — | 219 USD | — | 5.25 USD | 10.32 USD |
| 利息支出 | 106 USD | — | 3708 USD | 5249 USD | 1.03万 USD |
| 折旧和摊销 | 20.09万 USD | 33.75万 USD | 40.8万 USD | 43.52万 USD | 68.16万 USD |
| 营业利润 | −877.44万 USD | −963.23万 USD | −1644.84万 USD | −1996.14万 USD | −2594.45万 USD |
| 净利润 | −1213.15万 USD | −957.5万 USD | −1.73万 USD | −1850.43万 USD | −4897.69万 USD |
公司数据更新于 2026年10月13日。
近期已公布业绩
第三方分析师预期可能变化，并非 GoAI 建议。
评级样本有限，仅4项
| 行动 | 除息日 | 详情 | 记录日期 | 付款日期 |
|---|---|---|---|---|
股息 | 2008年4月23日 | US$0.021Irregular | 2008年4月15日 | — |
除息 2008年4月23日
US$0.021
Irregular
2008年4月15日登记
报告持有此股票敞口的交易所交易基金。
AI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
